食管癌的分子靶向治疗研究进展_West China Medical Journal

Authors：

鲜爽 ,  彭枫

Corresponding author：

彭枫, Email: xianyishuang@163.com

Keywords：

食管肿瘤; 靶向治疗

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

近年来，手术及放射、化学疗法在食管癌治疗方面取得了一定的进步，然而对食管癌患者并没有带来长期生存率的明显增高。分子靶向治疗在食管癌的应用逐渐受到越来越多的关注。目前，已有众多Ⅰ/Ⅱ期临床试验用于评估食管癌分子靶向治疗疗效。

Citation： 鲜爽,彭枫. 食管癌的分子靶向治疗研究进展. West China Medical Journal, 2012, 27(11): 1751-1753. doi: Copy

1.	Jemal A, Bray F, Center MM, et al. Global cancer statistics[J]. CA Cancer J Clin, 2011, 61(2): 69-90.
2.	Kim T, Grobmyer SR, Smith R, et al. Esophageal cancer: the five year survivors[J]. J Surg Oncol, 2011, 103(2): 179-183.
3.	孙晓江, 许亚萍. 表皮生长因子受体靶向抑制剂在食管癌中的应用[J]. 国际肿瘤学杂志, 2010, 37(12): 922-925.
4.	Liu QW, Fu JH, Luo KJ, et al. Identification of EGFR and KRAS mutations in Chinese patients with esophageal squamous cell carcinoma[J]. Dis Esophgus, 2011, 24(5): 374-380.
5.	Safran H, Suntharalingam M, Dipetrillo T, et al. Cetuximab with concurrent chemoradiation for esophagogastric cancer: assessment of toxicity[J]. Int J Radiat Oncol Biol Phys, 2008, 70(2): 391-395.
6.	Lorenzen S, Schuster T, Porschen R, et al. Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase Ⅱ study of the Arbeitsgemeinschaft Internistische Onkologie[J]. Ann Oncol, 2009, 20(10): 1667-1673.
7.	Ruhstaller T, Pless M, Dietrich D, et al. Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: a prospective, multicenter phase ⅠB/Ⅱ Trial (SAKK 75/06) [J]. J Clin Oncol, 2011, 29(6): 626-631.
8.	Gold PJ, Goldman B, Iqbal S, et al. Cetuximab as second-line therapy in patients with metastatic esophageal adenocarcinoma: a phaseⅡ Southwest Oncology Group Study (S0415)[J]. J Thorac Oncol, 2010, 5(9): 1472-1476.
9.	Chan JA, Blaszkowsky LS, Enzinger PC, et al. A multicenter phase Ⅱ trial of single agent cetuximab in advanced esophageal and gastric adenocarcinoma[J]. Ann Oncol, 2011, 22(6): 1367-1373.
10.	Rodriguez CP, Adelstein DJ, Rice TW, et al. A phaseⅡ study of perioperative concurrent chemoradiotherapy, gefitinib in locoregionally advanced esophagus and gastroesophageal junction cancer[J]. J Thorac Oncol, 2010, 5(2): 229-235.
11.	Janmaat ML, Gallegos-Ruiz MI, Rodriguez JA, et al. Predictive factors for outcome in a phaseⅡ study of gefitinib in secondline treatment of advanced esophageal cancer patients[J]. J Clin Oncol, 2006, 24 (10): 1612-1619.
12.	Ferry DR, Anderson M, Beddar K, et al. A phaseⅡ study of gefitinib monotherapy in advaned esophageal adenocarcinoma: evidence of gen expression, cellular, and clinical response[J]. Clin Cancer Res, 2007, 13(19): 5869-5875.
13.	Dragovich T, McCoy S, Fenoglio-Preiser CM, et al. Phase Ⅱ trial of erlotinib in gastroesophageal junction and gasric adenocarcinomas: SWOG 0127[J]. J Clin Oncol, 2006, 24(30): 4922- 4927.
14.	Li G, Hu W, Wang J, et al. PhaseⅡ study of concurrent chemoradiation in combination with erlotinib for locally advanced esophageal carcinoma [J]. Int J Radiat Oncol Biol Phys, 2010, 78(5): 1407-1412.
15.	Wainberg ZA, Lin LS, DiCarlo B, et al. PhaseⅡ trial of modified FOLFOX6 and erlotinib in patients with metastatic or advanced adenocarcinoma of the oesophagus and gastro-oesophageal junction[J]. Br J Cancer, 2011, 105(6): 760-765.
16.	Ferte C, Romano O, Mariette C, et al. FOLFIRI chemotherapy in patients with advanced non resectable esophageal or junctional adenocarcinoma: a pilot study[J]. J Chemother, 2011, 23(6): 358-361.
17.	Ilson DH, Kelsen D, Shan M, et al. A phase 2 trial of erlotinib in patiens with previously treated squamous cell and adenocarcinoma of the esophagus[J]. Cancer, 2011, 117(7): 1409-1414.
18.	Safran H, Dipetrillo T, Akerman P, et al. PhaseⅠ/Ⅱ study of trastuzumab, paclitaxel, cisplatin and radiation for locally advanced, HER2 overexpressing, esophageal adenocarcinoma[J]. Int J Radiat Oncol Biol Phys, 2007, 67(2): 405-409.
19.	Grávalos C, Gómez-Martín C, Rivera F, et al. PhaseⅡ study of trastuzumab and cisplatin as first-line therapy in patients with HER2-positive advanced gastric or gastroesophageal junction cancer[J]. Clin Transl Oncol, 2011, 13(3): 179-184.
20.	封巍, 祝淑钗. 血管内皮生长因子与食管癌关系研究进展[J]. 中国肿瘤, 2006, 15(9): 600-603.
21.	Ferrara N, Hillan KJ, Gerber HP, et al. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer[J]. Nat Rev Drug Discov, 2004, 3(5): 391-400.
22.	Shah MA, Jhawer M, llson DH, et al. PhaseⅡ study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma[J]. J Clin Oncol, 2011, 29(7): 868-874.
23.	Akutsu Y, Hanari N, Yusup G, et al. COX2 expression predicts resistance to chemoradiotherapy in esophageal squamous cell carcinoma[J]. Ann Surg Oncol, 2011, 18(10): 2946-2951.
24.	Dawson SJ, Michael M, Biagi J, et al. A phaseⅠ/Ⅱ trial of celecoxib with chemotherapy and radiotherapy in the treatment of patients with locally advanced oesophageal cancer[J]. Invest New Drugs, 2007, 25(2): 123-129.
25.	Altorki NK, Christos P, Port JL, et al. Preoperative taxane-based chemotherapy and celecoxib for carcinoma of the esophagus and gastroesophageal junction: results of a phase 2 trial[J]. J Thorac Oncol, 2011, 6(6): 1121-1127.
26.	Yu L, Chen M, Li Z, et al. Celecoxib antagonizes the cytotoxicity of cisplatin in human esophageal squamous cell carcinoma cells by reducing intracellular cisplatin accumulation[J]. Mol Pharmacol, 2011, 79(3): 608-617.

1. 　Jemal A, Bray F, Center MM, et al. Global cancer statistics[J]. CA Cancer J Clin, 2011, 61(2): 69-90.
2. 　Kim T, Grobmyer SR, Smith R, et al. Esophageal cancer: the five year survivors[J]. J Surg Oncol, 2011, 103(2): 179-183.
3. 　孙晓江, 许亚萍. 表皮生长因子受体靶向抑制剂在食管癌中的应用[J]. 国际肿瘤学杂志, 2010, 37(12): 922-925.
4. 　Liu QW, Fu JH, Luo KJ, et al. Identification of EGFR and KRAS mutations in Chinese patients with esophageal squamous cell carcinoma[J]. Dis Esophgus, 2011, 24(5): 374-380.
5. 　Safran H, Suntharalingam M, Dipetrillo T, et al. Cetuximab with concurrent chemoradiation for esophagogastric cancer: assessment of toxicity[J]. Int J Radiat Oncol Biol Phys, 2008, 70(2): 391-395.
6. 　Lorenzen S, Schuster T, Porschen R, et al. Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase Ⅱ study of the Arbeitsgemeinschaft Internistische Onkologie[J]. Ann Oncol, 2009, 20(10): 1667-1673.
7. 　Ruhstaller T, Pless M, Dietrich D, et al. Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: a prospective, multicenter phase ⅠB/Ⅱ Trial (SAKK 75/06) [J]. J Clin Oncol, 2011, 29(6): 626-631.
8. 　Gold PJ, Goldman B, Iqbal S, et al. Cetuximab as second-line therapy in patients with metastatic esophageal adenocarcinoma: a phaseⅡ Southwest Oncology Group Study (S0415)[J]. J Thorac Oncol, 2010, 5(9): 1472-1476.
9. 　Chan JA, Blaszkowsky LS, Enzinger PC, et al. A multicenter phase Ⅱ trial of single agent cetuximab in advanced esophageal and gastric adenocarcinoma[J]. Ann Oncol, 2011, 22(6): 1367-1373.
10. 　Rodriguez CP, Adelstein DJ, Rice TW, et al. A phaseⅡ study of perioperative concurrent chemoradiotherapy, gefitinib in locoregionally advanced esophagus and gastroesophageal junction cancer[J]. J Thorac Oncol, 2010, 5(2): 229-235.
11. 　Janmaat ML, Gallegos-Ruiz MI, Rodriguez JA, et al. Predictive factors for outcome in a phaseⅡ study of gefitinib in secondline treatment of advanced esophageal cancer patients[J]. J Clin Oncol, 2006, 24 (10): 1612-1619.
12. 　Ferry DR, Anderson M, Beddar K, et al. A phaseⅡ study of gefitinib monotherapy in advaned esophageal adenocarcinoma: evidence of gen expression, cellular, and clinical response[J]. Clin Cancer Res, 2007, 13(19): 5869-5875.
13. 　Dragovich T, McCoy S, Fenoglio-Preiser CM, et al. Phase Ⅱ trial of erlotinib in gastroesophageal junction and gasric adenocarcinomas: SWOG 0127[J]. J Clin Oncol, 2006, 24(30): 4922- 4927.
14. 　Li G, Hu W, Wang J, et al. PhaseⅡ study of concurrent chemoradiation in combination with erlotinib for locally advanced esophageal carcinoma [J]. Int J Radiat Oncol Biol Phys, 2010, 78(5): 1407-1412.
15. 　Wainberg ZA, Lin LS, DiCarlo B, et al. PhaseⅡ trial of modified FOLFOX6 and erlotinib in patients with metastatic or advanced adenocarcinoma of the oesophagus and gastro-oesophageal junction[J]. Br J Cancer, 2011, 105(6): 760-765.
16. 　Ferte C, Romano O, Mariette C, et al. FOLFIRI chemotherapy in patients with advanced non resectable esophageal or junctional adenocarcinoma: a pilot study[J]. J Chemother, 2011, 23(6): 358-361.
17. 　Ilson DH, Kelsen D, Shan M, et al. A phase 2 trial of erlotinib in patiens with previously treated squamous cell and adenocarcinoma of the esophagus[J]. Cancer, 2011, 117(7): 1409-1414.
18. 　Safran H, Dipetrillo T, Akerman P, et al. PhaseⅠ/Ⅱ study of trastuzumab, paclitaxel, cisplatin and radiation for locally advanced, HER2 overexpressing, esophageal adenocarcinoma[J]. Int J Radiat Oncol Biol Phys, 2007, 67(2): 405-409.
19. 　Grávalos C, Gómez-Martín C, Rivera F, et al. PhaseⅡ study of trastuzumab and cisplatin as first-line therapy in patients with HER2-positive advanced gastric or gastroesophageal junction cancer[J]. Clin Transl Oncol, 2011, 13(3): 179-184.
20. 　封巍, 祝淑钗. 血管内皮生长因子与食管癌关系研究进展[J]. 中国肿瘤, 2006, 15(9): 600-603.
21. 　Ferrara N, Hillan KJ, Gerber HP, et al. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer[J]. Nat Rev Drug Discov, 2004, 3(5): 391-400.
22. 　Shah MA, Jhawer M, llson DH, et al. PhaseⅡ study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma[J]. J Clin Oncol, 2011, 29(7): 868-874.
23. 　Akutsu Y, Hanari N, Yusup G, et al. COX2 expression predicts resistance to chemoradiotherapy in esophageal squamous cell carcinoma[J]. Ann Surg Oncol, 2011, 18(10): 2946-2951.
24. 　Dawson SJ, Michael M, Biagi J, et al. A phaseⅠ/Ⅱ trial of celecoxib with chemotherapy and radiotherapy in the treatment of patients with locally advanced oesophageal cancer[J]. Invest New Drugs, 2007, 25(2): 123-129.
25. 　Altorki NK, Christos P, Port JL, et al. Preoperative taxane-based chemotherapy and celecoxib for carcinoma of the esophagus and gastroesophageal junction: results of a phase 2 trial[J]. J Thorac Oncol, 2011, 6(6): 1121-1127.
26. 　Yu L, Chen M, Li Z, et al. Celecoxib antagonizes the cytotoxicity of cisplatin in human esophageal squamous cell carcinoma cells by reducing intracellular cisplatin accumulation[J]. Mol Pharmacol, 2011, 79(3): 608-617.

West China Medical Journal

食管癌的分子靶向治疗研究进展

Abstract Full text Figures/Tables Video References Cited by

Format

Content